Recent News

• 04.15.2025 - CollPlant's Collink.3D® BioInks and Technologies Offer a Relevant and Timely Solution to FDA's Plan to Reduce Animal Testing in Preclinical Safety Studies
• 03.26.2025 - 20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]
• 03.26.2025 - COLLPLANT BIOTECHNOLOGIES REPORTS 2024 FINANCIAL RESULTS AND PROVIDES A CORPORATE UPDATE
• 03.19.2025 - COLLPLANT BIOTECHNOLOGIES ANNOUNCES DATE FOR 2024 FOURTH QUARTER AND FULL YEAR 2024 FINANCIAL RESULTS AND CONFERENCE CALL INFORMATION
• 02.24.2025 - CollPlant Expands Distribution for its VergenixSTR Product in Europe and Asia
• 02.12.2025 - CollPlant Biotechnologies Provides a Corporate Update

Recent Filings

• 04.15.2025 - EX-99.1 EX-99.1
• 04.15.2025 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 03.26.2025 - EX-99.1 EX-99.1
• 03.26.2025 - 20-F Annual and transition report of foreign private issuers [Sections 13 or 15(d)]
• 03.26.2025 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 02.24.2025 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 02.24.2025 - EX-99.1 EX-99.1
• 02.12.2025 - EX-99.1 EX-99.1
• 02.12.2025 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 01.28.2025 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors